Scleroderma: Physical Performance and Functionality Study
Part of Skin clinical trials.
This study looks at how scleroderma affects physical performance and daily function in children and adults. It aims to understand the impact of the disease on movement and everyday activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with scleroderma
- You are 7 years or older
- You do not have a serious heart, lung, liver, kidney, or neurological disease, or cancer
- You have not been in a regular exercise program in the past 3 months
- You are willing to participate in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a special exercise program based on your body and mind can help people with scleroderma feel better. It is for both children (ages 7-18) and adults.
This trial looks at how systemic sclerosis affects daily function and mental well-being, including social and emotional factors. It may help patients understand their condition better.
This study looks at how scleroderma affects chewing and swallowing in children and adults. It aims to help understand these problems better so care can be improved.
This study is adapting a questionnaire to measure how scleroderma affects your daily life. Your responses will help make the tool more useful for Turkish-speaking patients.
This trial uses a simple 6-minute pegboard ring test to check how well your hands work. It aims to understand hand function in scleroderma and may help find new ways to track your health.
This study looks at whether people with systemic sclerosis (scleroderma) have weakness in the muscles they use to breathe. It aims to find out if measuring these muscles can help detect early breathing problems.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.